Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. 1987

K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim

Fifty-two pairs of patients with idiopathic diffuse mesangial proliferative glomerulonephritis entered a controlled 3-year prospective trial of a combination regimen of cyclophosphamide, dipyridamole and warfarin. In the treatment group proteinuria decreased significantly (p less than 0.01) and renal function remained stable, but in the control group there was no change in proteinuria and creatinine clearance (Ccr) decreased significantly (p less than 0.01). The time patients with renal impairment in the control group and those in the treatment group took to reach end stage renal failure was significantly different (6.1 years versus 8.9 years, p less than 0.02). Among the patients with IgA nephritis, those in the treatment group (n = 27) had stable renal function and a significant decrease in proteinuria (p less than 0.01) but in the control group (n = 21) there was a significant fall in Ccr (p less than 0.01) and rise in serum creatinine (p less than 0.02) with no change in proteinuria. Among 23 pairs of patients in the study who were matched for renal function and degree of glomerulosclerosis, those in the treatment group had stable renal function and decrease in proteinuria (p less than 0.01) whereas those in the control group had decreased Ccr (p less than 0.01) but no change in proteinuria.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
March 1998, Clinical nephrology,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
January 1997, Ryoikibetsu shokogun shirizu,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
July 1978, Laboratory investigation; a journal of technical methods and pathology,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
October 2004, Nihon rinsho. Japanese journal of clinical medicine,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
January 1993, Kidney international. Supplement,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
June 1982, Klinicheskaia meditsina,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
January 1991, Advances in experimental medicine and biology,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
December 1982, The International journal of pediatric nephrology,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
January 1980, Minerva nefrologica,
K T Woo, and R P Edmondson, and H K Yap, and A Y Wu, and G S Chiang, and E J Lee, and H S Pwee, and C H Lim
January 1979, Acta paediatrica Belgica,
Copied contents to your clipboard!